Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
1998

Advances in Pancreatic Cancer Treatment

Sample size: 63 publication Evidence: high

Author Information

Author(s): DD Von Hoff, AL Goodwin, L Garcia, The San Antonio Drug Development Team

Primary Institution: Institute for Drug Development, Cancer Therapy & Research Center

Hypothesis

Can gemcitabine improve symptoms and survival time in patients with pancreatic cancer?

Conclusion

Gemcitabine is the first new agent shown to improve symptoms and survival in patients with advanced pancreatic cancer.

Supporting Evidence

  • 23.8% of gemcitabine-treated patients experienced clinical benefit compared to 4.8% of those treated with 5-FU.
  • Median survival was 5.65 months for gemcitabine patients versus 4.41 months for 5-FU patients.
  • Patients with clinical benefit had a longer time until disease progression.

Takeaway

Gemcitabine helps people with pancreatic cancer feel better and live longer.

Methodology

A randomized trial comparing gemcitabine to 5-fluorouracil in patients with advanced pancreatic cancer.

Limitations

The study was not double-blinded due to safety concerns.

Participant Demographics

Patients with advanced pancreatic cancer, no prior chemotherapy, and measurable lesions.

Statistical Information

P-Value

0.0022

Statistical Significance

p=0.0022

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication